Martin is a graduate of Leeds University, UK (Pharmacology and Microbiology BSc) and obtained his PhD from the University of London (Institute and Cancer Research, Royal Marsden Hospital). Dr. Graham has R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA and has been involved in product approvals in US, Japan, Europe for drugs Oxaliplatin, Remicade, Stelara, Rasburicase, Mitoguazone, Tirapazamine, and Alfuzosin.

A senior executive with broad background in leadership, operations, strategic planning, and global business development. Proven ability to formulate strategy, establish and motivate cross-functional teams, develop and implement effective business solutions and deliver results.Janet leads all business development and organizational development initiatives.